Code
lsting <- as_listing(
out,
key_cols = c("TRT01A", "CRTNPT", "AGSXRC", "AVISIT", "ADY"),
disp_cols = names(out),
main_title = "Listing of ECG Data: Safety-Evaluable Patients",
main_footer = "Baseline is the patient's last observation prior to initiation of study drug. Abnormalities are flagged as high (H) or low (L) if outside the Roche standard reference range."
)
head(lsting, 20)Listing of ECG Data: Safety-Evaluable Patients
———————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————
Heart Rate Result QT Duration Result RR Duration Result
Study (beats/min); Heart Rate (msec); QT Duration (msec); RR Duration
Treatment Center/Subject ID Age/Sex/Race Visit Day Range:(40-100) Change from BL Range:(200-500) Change from BL Range:(600-1500) Change from BL
———————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————
A: Drug X BRA-1/105 38/M/BLACK OR AFRICAN AMERICAN BASELINE 149 66.94 NA 441.78 NA 896.59 NA
WEEK 1 DAY 8 314 63.18 -3.76 365.68 -76.10 1376.26 479.67
WEEK 2 DAY 15 398 57.57 -9.37 355.48 -86.29 799.57 -97.02
WEEK 3 DAY 22 470 73.36 6.42 352.45 -89.33 1015.00 118.41
WEEK 4 DAY 29 528 53.72 -13.22 388.42 -53.36 1189.29 292.70
WEEK 5 DAY 36 535 58.25 -8.69 291.77 -150.01 936.09 39.50
BRA-1/134 47/M/WHITE BASELINE 227 46.99 NA 385.29 NA 835.17 NA
WEEK 1 DAY 8 255 48.38 1.39 453.74 68.46 901.86 66.68
WEEK 2 DAY 15 269 35.40/L -11.59 413.54 28.26 892.01 56.84
WEEK 3 DAY 22 357 60.50 13.51 394.23 8.95 490.18/L -344.99
WEEK 4 DAY 29 436 82.28 35.29 398.29 13.00 757.96 -77.21
WEEK 5 DAY 36 440 38.89/L -8.10 339.38 -45.91 880.26 45.08
BRA-1/42 36/M/BLACK OR AFRICAN AMERICAN BASELINE 477 56.19 NA 190.94/L NA 1276.65 NA
WEEK 1 DAY 8 534 85.24 29.05 483.71 292.77 735.11 -541.54
WEEK 2 DAY 15 550 55.53 -0.66 386.60 195.66 1092.71 -183.94
WEEK 3 DAY 22 569 65.37 9.18 311.08 120.14 1227.15 -49.50
WEEK 4 DAY 29 608 65.13 8.93 329.78 138.83 250.18/L -1026.47
WEEK 5 DAY 36 675 49.03 -7.16 470.67 279.73 1321.21 44.56
BRA-1/93 34/F/ASIAN BASELINE 73 72.12 NA 306.64 NA 1324.80 NA
WEEK 1 DAY 8 207 66.88 -5.24 190.50/L -116.14 1495.37 170.58
———————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————
Baseline is the patient's last observation prior to initiation of study drug. Abnormalities are flagged as high (H) or low (L) if outside the Roche standard reference range.